Associated Papers
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
A base editing platform for the correction of cancer driver mutations unmasks conserved p53 transcription programs.
Wang P et al.
Genome Biology, 2025
40696461 (PubMed )
Supplement: 13059_2025_3667_MOESM1_ESM.xlsx › Overlap_between_lines
Ku70 senses cytosolic DNA and assembles a tumor-suppressive signalosome.
Pandey A et al.
Science Advances, 2024
The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells.
Chapdelaine AG et al.
Cancers, 2023
Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential.
Voutsadakis IA
Medicina (kaunas, Lithuania), 2022
AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B.
Xu J et al.
Cancer Discovery, 2021
Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer.
Nam GH et al.
Journal for Immunotherapy of Cancer, 2021
The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis.
Tu J et al.
Scientific Reports, 2019
31811196 (PubMed )
Supplement: 41598_2019_54931_MOESM1_ESM.pdf
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.
Wyce A et al.
Oncogenesis, 2018
29674704 (PubMed )
Supplement: 41389_2018_43_MOESM5_ESM.pdf
Select a paper to view details